Edwards Lifesciences (NYSE:EW) Stock Price Expected to Rise, UBS Group Analyst Says

Key Points

• UBS raised its price target on Edwards Lifesciences to $118 from $110 and maintained a Buy rating, implying 17.18% upside from the previous close.
• Analyst sentiment is broadly positive: the stock has a consensus “Moderate Buy” rating from 23 Buy and three Hold recommendations, with an average target of $108.88.
• Edwards beat quarterly expectations, reporting EPS of $0.80 versus $0.74 forecast and revenue of $1.72 billion versus $1.68 billion expected; revenue rose 10.5% year over year.

Edwards Lifesciences (NYSE:EW - Get Free Report) had its price objective increased by equities research analysts at UBS Group from $110.00 to $118.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a "buy" rating on the medical research company's stock. UBS Group's price target suggests a potential upside of 17.18% from the company's previous close.

A number of other equities analysts have also commented on EW. TD Cowen reissued a "buy" rating on shares of Edwards Lifesciences in a research note on Tuesday, October 27th. Citigroup upped their price objective on Edwards Lifesciences from $110.00 to $117.00 and gave the stock a "buy" rating in a report on Thursday. Wells Fargo & Company reiterated an "overweight" rating and set a $113.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Thursday. Royal Bank Of Canada boosted their price target on shares of Edwards Lifesciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Thursday. Finally, Wall Street Zen downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Saturday, October 31st. Twenty-three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $108.88.

Edwards Lifesciences Price Performance

EW traded up $1.33 during trading on Thursday, hitting $100.70. 9,233,527 shares of the company traded hands, compared to its average volume of 4,532,402. The company has a market cap of $57.99 billion, a PE ratio of 57.88, a P/E/G ratio of 2.49 and a beta of 0.85. The stock's 50-day simple moving average is $88.68 and its two-hundred day simple moving average is $85.69. Edwards Lifesciences has a 1 year low of $74.66 and a 1 year high of $104.17. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The medical research company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.74 by $0.06. The business had revenue of $1.72 billion for the quarter, compared to analysts' expectations of $1.68 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business's quarterly revenue was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.67 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences will post 3.00 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Annette Brüls sold 2,644 shares of the stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the sale, the vice president owned 17,984 shares in the company, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of Edwards Lifesciences stock in a transaction on Thursday, October 8th. The stock was sold at an average price of $85.65, for a total transaction of $53,017.35. Following the transaction, the vice president directly owned 40,034 shares of the company's stock, valued at $3,428,912.10. The trade was a 1.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 5,045 shares of company stock valued at $451,596 in the last ninety days. Insiders own 0.31% of the company's stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several institutional investors have recently made changes to their positions in EW. Pin Oak Investment Advisors Inc. acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at $26,000. TrinityBridge Ltd acquired a new position in Edwards Lifesciences during the second quarter worth $27,000. GK Wealth Management LLC acquired a new position in Edwards Lifesciences during the third quarter worth $26,000. RMG Wealth Management LLC acquired a new position in Edwards Lifesciences during the first quarter worth $26,000. Finally, Compass Financial Management LLC purchased a new position in Edwards Lifesciences during the second quarter valued at $32,000. Institutional investors own 79.46% of the company's stock.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Q3 results and outlook beat expectations. Edwards reported adjusted EPS of $0.80 versus $0.74 expected and revenue of $1.72 billion versus $1.68 billion, with sales up 11.2% year over year. Strength in structural heart therapies supported margin growth, and the company raised its full-year adjusted EPS outlook to $2.97–$3.05. Edwards Q3 earnings and revenue
• Positive Sentiment: Growth across key therapies supports the outlook. TMTT sales surged 45.6% and TAVR sales grew 8.8%. The company also expects procedure volumes to benefit from positive study results and expanded Medicare reimbursement. Q3 earnings call highlights
• Positive Sentiment: Clinical findings may broaden the addressable market. PROGRESS Trial data indicated TAVR reduced combined death or heart-failure outcomes versus active surveillance in at-risk patients with moderate aortic stenosis, with fewer heart-failure hospitalizations and better quality-of-life measures. PROGRESS Trial data
• Positive Sentiment: Analysts raised targets and ratings. Several firms lifted price targets, including Barclays to $120, Citigroup to $117 and JPMorgan to $120. Baird and Truist upgraded the stock, while multiple firms reiterated positive ratings, reflecting increased confidence after the quarterly report.
• Negative Sentiment: Competition remains a risk. Edwards’ CEO cautioned that more competition is coming in the TAVR market, which could pressure future growth or market share. CEO comments on TAVR competition

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart's valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.